Pipeline
Our Development Model
GeminiVax follows a milestone-based development model:
-
Pathogen and strain-diversity analysis
-
Epitope and antigen-cassette design
-
Vector construction
-
In vitro characterisation
-
Preclinical immunogenicity testing
-
Target-animal safety and immunology
-
Challenge studies
-
Field evaluation
-
Licensing, co-development or registration partnership
Universal Swine Influenza Vaccine
GeminiVax is developing a broadly protective swine influenza vaccine candidate designed to address H1N1, H1N2 and H3N2 lineages through vector-based delivery and rationally selected conserved immune targets.
PRRSV Vaccine
GeminiVax is developing a PRRSV vaccine candidate designed to address PRRSV-1 and PRRSV-2 diversity through conserved immune targets, with particular emphasis on cellular immune responses relevant to highly variable viral pathogens.
PCV-2 Vaccine
GeminiVax is developing a broad-coverage PCV-2 vaccine candidate designed to address major genotypes, including PCV2a, PCV2b, PCV2d and emerging variants, using epitope-guided antigen selection and vector-based delivery.
Classic Swine Fever Vaccine
Classical swine fever is a highly important transboundary viral disease of pigs, with major implications for animal health, outbreak control, trade and national disease-eradication programmes.
Vaccination strategies for CSF may require not only protective immunity, but also compatibility with surveillance systems and differentiation between infected and vaccinated animals.
